VTVT - vTv Therapeutics Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.69
-0.05 (-1.34%)
At close: 4:00PM EDT

3.60 -0.09 (-2.44%)
After hours: 6:28PM EDT

Stock chart is not supported by your current browser
Previous Close3.74
Open3.40
Bid3.60 x 1100
Ask3.70 x 1100
Day's Range3.38 - 3.75
52 Week Range0.65 - 8.40
Volume1,030,038
Avg. Volume2,727,684
Market Cap143.418M
Beta (3Y Monthly)1.49
PE Ratio (TTM)N/A
EPS (TTM)-1.43
Earnings DateOct 31, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Market Exclusive6 days ago

    Stock Market News Daily Roundup October 17

    Shares of International Business Machines (NYSE: IBM) are down 5% today as the company topped Wall Street expectations for third-quarter earnings but missed Street estimates for revenue. The company reported a total revenue of $18.76 billion, down from $19.15 billion a year ago. Analysts estimated $19.10 billion in revenue for the third quarter. Netflix, Inc. […] The post Stock Market News Daily Roundup October 17 appeared first on Market Exclusive.

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...

  • Business Wire7 days ago

    vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference on October 24-27, 2018 in Barcelona, Spain. The oral presentation will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease.

  • ACCESSWIRE8 days ago

    vTv Therapeutics Shares Soar in October, Near Term Catalysts, Analysts review and Target

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. Despite the lack of company news or announced catalyst, VTVT shares have jumped from $.78 per share to the current price of $3.45 thus far in October. Since its recent announcement regarding the topline results from Part B of the STEADFAST Study, VTVT has continued to analyze the results from Parts A and B and are encouraged by its findings.

  • vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session
    Zacks12 days ago

    vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session

    vTv Therapeutics (VTVT) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

  • ACCESSWIRE13 days ago

    This Week’s Biotech and Cannabis Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / October 10, 2018 / Stocks in the biotech and cannabis industries provide investors the largest gains. That’s why we always have our ear to the ground for the best opportunities ...

  • ACCESSWIRE13 days ago

    Today’s Research Reports on Stocks to Watch: Trevena and vTv Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 10, 2018 / Trevena shares sank yesterday on remarks from the Food & Drug Administration on the company’s opioid injection. The FDA has said the treatment could lead ...

  • ACCESSWIRE19 days ago

    Undervalued Stocks You Can’t Afford to Miss

    DYAI has over $40 million in the bank, a stock buyback agreement, and entered into an additional fully funded research collaboration with Sanofi-Aventis to test the feasibility of using C1 to produce multiple genes for vaccine and drug applications. For those that do not know Sanofi-Aventis is over a $100 Billion company that trades on the New York Stock Exchange. DYAI currently has assets on its balance sheet of over $49 Million while only has a market cap of $46 Million.

  • ACCESSWIRE20 days ago

    Today’s Research Reports on Stocks to Watch: Inovio Pharmaceuticals and vTV Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Inovio Pharmaceuticals saw its shares climb over 14% by the close on Tuesday as traders digested positive data that was published in Clinical Cancer Research. ...

  • Business Wire2 months ago

    vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting company at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 4-6, 2018, at The St. Regis Hotel in New York City. vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. This release contains forward-looking statements, which involve risks and uncertainties.

  • VTv Therapeutics (VTVT) Reports Q2 Loss, Tops Revenue Estimates
    Zacks3 months ago

    VTv Therapeutics (VTVT) Reports Q2 Loss, Tops Revenue Estimates

    vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -16.00% and 0.69%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    VTv Therapeutics: 2Q Earnings Snapshot

    On a per-share basis, the High Point, North Carolina-based company said it had a loss of 31 cents. Losses, adjusted for non-recurring costs, came to 29 cents per share. The results fell short of Wall Street ...

  • Business Wire3 months ago

    vTv Therapeutics Announces Second Quarter 2018 Results and Update

    vTv Therapeutics Inc. today reported financial results for the second quarter that ended June 30, 2018, and provided an update on recent achievements and upcoming events.

  • ACCESSWIRE3 months ago

    Breakfast Technical Briefing on ZIOPHARM Oncology and Three Other Additional Biotech Stocks

    For today, WallStEquities.com assesses vTv Therapeutics Inc. (NASDAQ: VTVT), Voyager Therapeutics Inc. (NASDAQ: VYGR), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), and Zosano Pharma Corp. (NASDAQ: ZSAN). High Point, North Carolina headquartered vTv Therapeutics Inc.'s stock saw a decline of 3.70%, finishing last Friday's trading session at $1.30. The Company's shares are trading below their 50-day moving average by 19.58%.

  • ACCESSWIRE4 months ago

    Initiating Free Research Reports on ZIOPHARM Oncology and Three Other Biotech Equities

    Stock Research Monitor: VYGR, VTVT, and ZSAN LONDON, UK / ACCESSWIRE / July 2, 2018 / If you want a free Stock Review on ZIOP sign up now at www.wallstequities.com/registration . WallStEquities.com recalls ...

  • Business Wire4 months ago

    vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that Company management will present a poster featuring vTv Therapeutics’ liver-selective Glucokinase Activator at the American Diabetes Association’s 78th Scientific Sessions held in Orlando, Fla., June 22–26, 2018. “As the first company to evaluate a Glucokinase Activator in people with type 1 diabetes, we are very excited to be sharing this clinical data at the American Diabetes Association’s 78th Scientific Sessions,” said Carmen Valcarce, Ph.D., executive vice president, chief scientific officer, vTv Therapeutics.

  • Business Wire4 months ago

    vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study

    vTv Therapeutics Inc. (VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints. The prespecified subgroup consisted of azeliragon-treated patients with maximal azeliragon plasma concentrations of less than 7.5 ng/mL and baseline Mini Mental State Examination (MMSE) scores between 19 and 27, and the endpoints were statistically significant improvement in cognitive or functional outcomes as measured by the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) at 12-months compared to placebo.

  • vTv Therapeutics (VTVT) Catches Eye: Stock Jumps 6.9%
    Zacks5 months ago

    vTv Therapeutics (VTVT) Catches Eye: Stock Jumps 6.9%

    vTv Therapeutics (VTVT) shares rose nearly 7% in the last trading session, amid huge volumes.

  • Business Wire5 months ago

    vTv Therapeutics Announces Licensing Agreement with Newsoara Biopharma Co. Ltd. to Rights for vTv’s PDE4 Inhibitor in China and Other Pacific Rim Territories

    vTv Therapeutics Inc. (VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in mainland China, Hong Kong, Macau, Taiwan and other Pacific Rim countries covering Thailand, Vietnam, Indonesia, Malaysia, Philippines, Singapore, Myanmar, Cambodia, Laos, Brunei and South Korea. Under the terms of the agreement, vTv Therapeutics will receive an upfront payment and will be eligible to receive future development and commercialization milestones as well as royalties on sales of approved products. Newsoara will develop HPP737 in the covered territories for respiratory and other inflammatory diseases.

  • ACCESSWIRE5 months ago

    Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

    Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79.

  • Associated Press5 months ago

    VTv Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the High Point, North Carolina-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...